Biomarkers in osteoarthritis: current status and outlook — the FNIH Biomarkers Consortium PROGRESS OA study
David J. Hunter, Jamie E. Collins, Leticia A. Deveza, Steven C. Hoffmann, Virginia B. Kraus
Abstract
Currently, no disease-modifying therapies are approved for osteoarthritis (OA) use. One obstacle to trial success in this field has been our existing endpoints' limited validity and responsiveness. To overcome this impasse, the Foundation for the NIH OA Biomarkers Consortium is focused on investigating biomarkers for a prognostic context of use for subsequent qualification through regulatory agencies. This narrative review describes this activity and the work underway, focusing on the PROGRESS OA study.
Topics & Concepts
MedicineContext (archaeology)OsteoarthritisNarrative reviewClinical trialMedical physicsPhysical therapyIntensive care medicineAlternative medicineInternal medicinePathologyBiologyPaleontologyOsteoarthritis Treatment and MechanismsInflammatory mediators and NSAID effectsCytokine Signaling Pathways and Interactions